{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:27:44Z","timestamp":1787149664449,"version":"build-2736575974"},"reference-count":27,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T00:00:00Z","timestamp":1755388800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2025,7,29]]},"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1136\/ejhpharm-2025-004516","type":"journal-article","created":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T22:15:16Z","timestamp":1755468916000},"page":"450-454","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements"],"prefix":"10.1136","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4251-8011","authenticated-orcid":false,"given":"Ina","family":"Barzel","sequence":"first","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Dietert C","family":"Brugma","sequence":"additional","affiliation":[{"name":"Department of Outpatient Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin H","family":"Jacobs","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Hoogeveen-Westerveld","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7128-8801","authenticated-orcid":false,"given":"P Hugo M","family":"van der Kuy","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Preijers","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,17]]},"reference":[{"key":"2026081906551074000_33.5.450.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61555-X"},{"key":"2026081906551074000_33.5.450.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909859"},{"key":"2026081906551074000_33.5.450.3","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"2026081906551074000_33.5.450.4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-5275-3"},{"key":"2026081906551074000_33.5.450.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6293-5"},{"key":"2026081906551074000_33.5.450.6","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J Inherit Metab Dis"},{"key":"2026081906551074000_33.5.450.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8219-8"},{"key":"2026081906551074000_33.5.450.8","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10545-018-0166-3","article-title":"Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy","volume":"41","author":"van der Meijden","year":"2018","journal-title":"J Inherit Metab Dis"},{"key":"2026081906551074000_33.5.450.9","first-page":"e1756","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology (ECronicon)"},{"key":"2026081906551074000_33.5.450.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2011.04.001"},{"key":"2026081906551074000_33.5.450.11","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology (ECronicon)"},{"key":"2026081906551074000_33.5.450.12","unstructured":"EPAR product information: European Medicines Agency. 2024. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/myozyme-epar-product-information_en.pdf [Accessed 16 Sep 2024]."},{"key":"2026081906551074000_33.5.450.13","doi-asserted-by":"crossref","unstructured":"Desai AK , Walters CK , Cope HL , et al . Enzyme replacement therapy with alglucosidase alfa in Pompe disease: clinical experience with rate escalation. Mol Genet Metab 2018;92\u20136. doi:10.1016\/j.ymgme.2017.12.435","DOI":"10.1016\/j.ymgme.2017.12.435"},{"key":"2026081906551074000_33.5.450.14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40259-023-00609-2","article-title":"Home-Based Infusion of Alglucosidase Alfa Can Safely be Implemented in Adults with Late-Onset Pompe Disease: Lessons Learned from 18,380 Infusions","volume":"PMCID","author":"Ditters","year":"2023","journal-title":"BioDrugs"},{"key":"2026081906551074000_33.5.450.15","doi-asserted-by":"crossref","unstructured":"Ditters IAM , Beek N , Brusse E , et al . Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study. Orphanet J Rare Dis 2023;108. doi:10.1186\/s13023-023-02715-4","DOI":"10.1186\/s13023-023-02715-4"},{"key":"2026081906551074000_33.5.450.16","unstructured":"Available: https:\/\/www.gipdatabank.nl\/databank?infotype=d&label=00-totaal&tabel_d_00-totaal=B_01-basis&geg=vg&spec=&item=A16AB [Accessed 17 Nov 2024]."},{"key":"2026081906551074000_33.5.450.17","doi-asserted-by":"crossref","unstructured":"Ploeg AT , Kroos MA , Willemsen R , et al . Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest 1991;513\u20138. doi:10.1172\/JCI115025","DOI":"10.1172\/JCI115025"},{"key":"2026081906551074000_33.5.450.18","doi-asserted-by":"crossref","unstructured":"Bijvoet AG , Hirtum H , Kroos MA , et al . Human acid alpha-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet 1999;2145\u201353. doi:10.1093\/hmg\/8.12.2145","DOI":"10.1093\/hmg\/8.12.2145"},{"key":"2026081906551074000_33.5.450.19","doi-asserted-by":"crossref","unstructured":"Bijvoet AG , Kroos MA , Pieper FR , et al . Recombinant human acid alpha-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet 1998;1815\u201324. doi:10.1093\/hmg\/7.11.1815","DOI":"10.1093\/hmg\/7.11.1815"},{"key":"2026081906551074000_33.5.450.20","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s10545-009-1082-3","article-title":"Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates","volume":"32","author":"van Diggelen","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"2026081906551074000_33.5.450.21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J Inherit Metab Dis"},{"key":"2026081906551074000_33.5.450.22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/gim.2016.70","article-title":"Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy","volume":"19","author":"de Vries","year":"2017","journal-title":"Genet Med"},{"key":"2026081906551074000_33.5.450.23","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1002\/jps.23242","article-title":"Protein particles: what we know and what we do not know","volume":"101","author":"Ripple","year":"2012","journal-title":"J Pharm Sci"},{"key":"2026081906551074000_33.5.450.24","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.001593"},{"key":"2026081906551074000_33.5.450.25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cccn.2005.05.025","article-title":"Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease","volume":"361","author":"Umapathysivam","year":"2005","journal-title":"Clin Chim Acta"},{"key":"2026081906551074000_33.5.450.26","article-title":"Acid \u03b1-glucosidase (GAA) activity and glycogen content in muscle biopsy specimens of patients with Pompe disease: a systematic review","volume":"39","author":"Schoser","year":"2024","journal-title":"Mol Genet Metab Rep"},{"key":"2026081906551074000_33.5.450.27","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3390\/cells12141846","article-title":"Targeted Protein Degradation: Principles and Applications of the Proteasome","volume":"12","author":"Kim","year":"2023","journal-title":"Cells"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2025-004516","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:55:33Z","timestamp":1787147733000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2025-004516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,17]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/ejhpharm-2025-004516"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2025-004516","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,17]]}}}